...
首页> 外文期刊>BMC Cancer >Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
【24h】

Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery

机译:KRAS,BRAF和PI3KCA突变对新辅助放化疗和手术治疗的直肠癌的影响

获取原文

摘要

Background Conventional treatment for locally advanced rectal cancer usually combines neoadjuvant radiochemotherapy and surgery. Until recently, there have been limited predictive factors (clinical or biological) for rectal tumor response to conventional treatment. KRAS , BRAF and PIK3CA mutations are commonly found in colon cancers. In this study, we aimed to determine the mutation frequencies of KRAS , BRAF and PIK3CA and to establish whether such mutations may be used as prognostic and/or predictive factors in rectal cancer patients. Methods We retrospectively reviewed the clinical and biological data of 98 consecutive operated patients between May 2006 and September 2009. We focused in patients who received surgery in our center after radiochemotherapy and in which tumor samples were available. Results In the 98 patients with a rectal cancer, the median follow-up time was 28.3 months (4–74). Eight out of ninety-eight patients experienced a local recurrence (8%) and 17/98 developed distant metastasis (17%). KRAS, BRAF and PIK3CA were identified respectively in 23 (23.5%), 2 (2%) and 4 (4%) patients. As described in previous studies, mutations in KRAS and BRAF were mutually exclusive. No patient with local recurrence exhibited KRAS or PIK3CA mutation and one harbored BRAF mutation (12.5%). Of the seventeen patients with distant metastasis (17%), 5 were presenting KRAS mutation (29%), one BRAF (5%) and one PIK3CA mutation (5%). No relationship was seen between PIK3CA , KRAS or BRAF mutation and local or distant recurrences. Conclusion The frequencies of KRAS , BRAF and PIK3CA mutations in our study were lower than the average frequencies reported in colorectal cancers and no significant correlation was found between local/distant recurrences and KRAS , BRAF or PIK3CA mutations. Future studies with greater number of patients, longer follow-up time and greater power to predict associations are necessary to fully understand this relationship.
机译:背景技术局部晚期直肠癌的常规治疗通常结合新辅助放化疗和手术。直到最近,对于直肠肿瘤对常规治疗的反应的预测因素(临床或生物学的)还是有限的。 KRAS,BRAF和PIK3CA突变通常在结肠癌中发现。在这项研究中,我们旨在确定KRAS,BRAF和PIK3CA的突变频率,并确定这些突变是否可用作直肠癌患者的预后和/或预测因素。方法我们回顾性研究了2006年5月至2009年9月间98例连续手术患者的临床和生物学数据。我们的研究对象为放射化学疗法后在我们中心接受手术治疗且有肿瘤样本的患者。结果在98例直肠癌患者中,中位随访时间为28.3个月(4–74)。在98位患者中,有8位经历了局部复发(8%),而17/98发生了远处转移(17%)。在23例(23.5%),2例(2%)和4例(4%)患者中分别确定了KRAS,BRAF和PIK3CA。如先前的研究所述,KRAS和BRAF中的突变是互斥的。没有局部复发的患者表现出KRAS或PIK3CA突变,并且一个具有BRAF突变(12.5%)。在17例远处转移的患者中(17%),有5例出现KRAS突变(29%),1例BRAF(5%)和1例PIK3CA突变(5%)。在PIK3CA,KRAS或BRAF突变与局部或远处复发之间没有关系。结论本研究中KRAS,BRAF和PIK3CA突变的频率低于大肠癌报道的平均频率,且局部/远处复发与KRAS,BRAF或PIK3CA突变之间无显着相关性。为了充分了解这种关系,有必要进行更多患者,更长的随访时间和更大的预测关联的未来研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号